trending Market Intelligence /marketintelligence/en/news-insights/trending/7xbrvr0wcmuiwag-3mpyma2 content esgSubNav
In This List

G1 Therapeutics adds 2 board members

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


G1 Therapeutics adds 2 board members

G1 Therapeutics Inc. said June 8 that it added Cynthia Schwalm and Willie Deese to its board as independent directors.

Schwalm was most recently president and CEO of Ipsen SA's North America division.

Meanwhile, Deese previously served as the president of Merck & Co. Inc.'s manufacturing unit. He was also a member of Merck's executive committee until he retired in 2016.

Schwalm and Deese are filling board vacancies left by Christy Schaffer and Tyrell Rivers, who left the board after their terms as directors expired.

Research Triangle Park, N.C.-based G1 Therapeutics discovers and develops treatments for cancer.